Entering text into the input field will update the search result below

Obalon Therapeutics down 13% premarket on Q4 results

  • Obalon Therapeutics (OBLN) Q4 results:
  • Revenues: $0.9M (-55.0%).
  • Net loss: ($4.9M) (+44.3%); loss/share: ($0.64) (+83.5%); CF Ops: ($22.9M) (+22.1%).
  • Key Accomplishments in 2019: Promoted Bill Plovanic from CFO to President and CEO.
  • Appointed Bob MacDonald as Chief Retail Officer.
  • Promoted Nooshin Hussainy from Vice President of Finance to CFO.
  • Entered into one-year distribution agreement with distributor for Qatar.
  • Opened the first Obalon-managed retail treatment center in San Diego.
  • Commercialized Obalon Navigation System and Obalon Touch Inflation Dispenser.
  • Shares are down 13% premarket.
  • Previously: Obalon Therapeutics EPS misses by $0.09, beats on revenue (Feb. 27)

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
OBLN--
Obalon Therapeutics, Inc.